Home Newsfeeds Zions Bancorporation’s Board Approves Buyback Program Of Up To $50M

Zions Bancorporation’s Board Approves Buyback Program Of Up To $50M

Zions Bancorporation, N.A. (NASDAQ:ZION) announced today that its board of directors ("board") authorized a share repurchase for the third quarter of 2022 of up to $50 million.

byBenzinga Newsdesk

July 29, 2022

1 minute read

Zions Bancorporation, N.A. (NASDAQ:ZION) announced today that its board of directors (“board”) authorized a share repurchase for the third quarter of 2022 of up to $50 million.

Missed Taylor Swift’s Eras Tour? Apple’s Got Your Back — Here’s What You Need To Know

By Rounak Jain

December 2, 4:32 AM

To honor Taylor Swift's designation as its "Artist of the Year", Apple is organizing a free "Taylor Swift Eras Experience" in New York City.

AAPL

DoorDash Shares Are Higher After-Hours: What’s Going On?

By AJ Fabino

February 16, 5:32 PM

Shares of DoorDash Inc (NYSE: DASH) are higher after-hours Thursday following the company’s fourth-quarter earnings results. Here’s what investors should know.

DASH

Hope for Kidney Cancer Patients, Merck’s Keytruda Cuts Risk Of Death By 38% Following Surgery

By Vandana Singh

January 29, 9:23 AM

Results from Merck's Phase 3 KEYNOTE-564 trial. Keytruda, an adjuvant treatment for renal cell carcinoma, shows a 38% improvement in overall survival at 57.2 months.

MRK

Credit Suisse Maintains Outperform on UnitedHealth Group, Raises Price Target to $590

By Benzinga Newsdesk

October 17, 7:14 AM

Credit Suisse analyst A.J. Rice maintains UnitedHealth Group (NYSE:UNH) with a Outperform and raises the price target from $579 to $590.

UNH

Zions Bancorporation’s Board Approves Buyback Program Of Up To $50M

Related Posts

Missed Taylor Swift’s Eras Tour? Apple’s Got Your Back — Here’s What You Need To Know

DoorDash Shares Are Higher After-Hours: What’s Going On?

Hope for Kidney Cancer Patients, Merck’s Keytruda Cuts Risk Of Death By 38% Following Surgery

Credit Suisse Maintains Outperform on UnitedHealth Group, Raises Price Target to $590